Abstract. Background/Aim: Outcomes of elderly patients with cerebral metastases from kidney cancer may be improved by personalized treatment. A scoring instrument for estimating survival in these patients is presented. Patients and Methods: Twenty-four elderly kidney cancer patients receiving whole-brain irradiation (WBI) were retrospectively investigated. WBI-regimen and six pre-treatment factors were evaluated including age, gender, performance score, number of cerebral metastases, extracranial metastases and time from kidney cancer diagnosis to WBI. Results: Number of cerebral metastases (p=0.194) and time from kidney cancer diagnosis to WBI (p=0.107) correlated with survival and were included in the instrument. Based on these factors, patient scores of 0, 1 and 2 points resulted in 6-month survival rates of 0%, 15% and 60% (p=0.131), respectively. Two groups were designed, 0-1 and 2 points, with 6-month survival rates of 11% and 60% (p=0.108), respectively. Conclusion: This new instrument can assist physicians aiming to estimate a patient’s survival prognosis to provide personalized treatment.

Approximately 10% of patients with kidney cancer develop cerebral metastases, and kidney cancer accounts for about 4% of solid tumors associated with cerebral metastases in adult cancer patients (1, 2). Many patients with a limited number of cerebral metastases (mainly defined as 1-3 or 1-4 lesions) from kidney cancer receive stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) (3-6). The majority of kidney cancer patients with multiple (mainly defined as >3 or >4 lesions) cerebral metastases receive whole-brain irradiation (WBI) (7-9). For patients with kidney cancer, WBI-doses higher than 30 Gy were reported to result in better survival and local (intracerebral) control than 10×3 Gy (10). Of the patients with cerebral metastases from kidney cancer, about 25% are aged ≥65 years (elderly patients) (3-10). Since these patients often have poor performance scores and significant comorbidities, they may not be able to sufficiently tolerate intensive local therapies such as SRS and FSRT or WBI with higher biologically effective doses. Some benefits of local therapies and higher-dose WBI in terms of less late toxicity and improved local control are more of an issue in patients with favorable survival prognoses (1, 3-10). Moreover, patients with a poor survival are better treated with short-course WBI to keep the time spent receiving anticancer treatment to a minimum (11).

Therefore, it is important to estimate a patient’s lifespan before assigning a treatment program. This study aimed to provide an instrument that can assist physicians in estimating the survival prognosis of elderly patients with cerebral metastases from kidney cancer.

Patients and Methods

A total of 24 elderly patients (65 years or older) with kidney cancer, who had developed cerebral metastases, were included in this retrospective study. The data of some of these patients were obtained from an existing database partly used for previous studies (8-12). The current study received approval from the Ethics Committee of the University of Lübeck (reference 19-011A). All 24 patients were treated with WBI alone, either with 5×4 Gy (1 week), 10×3 Gy (2 weeks) or total doses >30 Gy (doses per fraction of 2-3 Gy, 3-4 weeks). The WBI-regimen and six pre-treatment factors (Table I) were evaluated for associations with survival. These factors included age (≤70 vs. ≥71 years), gender, performance status (Karnofsky performance score (KPS) of <70 vs. ≥70), number of cerebral metastases (limited, 1-3 lesions vs. multiple, >3 lesions), extracranial metastases at the start of WBI (no vs. yes), and the time from kidney cancer diagnosis to WBI (<24 vs. ≥24 months).

For survival analyses, we used the Kaplan–Meier method supplemented by the log-rank test. The scoring instrument for estimation of survival was based on the factors showing a trend
(p<0.20) with respect to survival. For each factor included in the scoring instrument, 0 points (less favorable survival) and 1 point (more favorable survival) were awarded. The points of the factors were added for each patient to receive the so-called patient score.

**Table I. Summary of the factors analyzed for potential associations with survival.**

| Factor                                      | Number of patients (%) |
|---------------------------------------------|------------------------|
| Radiation regimen                           |                        |
| 5×4 Gy                                      | 4 (16.7)               |
| 10×3 Gy                                     | 12 (50.0)              |
| >30 Gy (2-3 Gy per fraction)                | 8 (33.3)               |
| Age                                         |                        |
| ≤75 Years                                   | 9 (37.5)               |
| ≥76 Years                                   | 15 (62.5)              |
| Gender                                      |                        |
| Female                                      | 9 (37.5)               |
| Male                                        | 15 (62.5)              |
| Karnofsky performance score                 |                        |
| <60                                         | 11 (45.8)              |
| ≥70                                         | 13 (54.2)              |
| Number of cerebral metastases               |                        |
| Limited (1-3)                               | 7 (29.2)               |
| Multiple (>3)                               | 17 (70.8)              |
| Extra-cranial metastases at the start of WBI|                        |
| No                                          | 9 (37.5)               |
| Yes                                         | 15 (62.5)              |
| Time from kidney cancer diagnosis to WBI    |                        |
| <24 Months                                  | 8 (33.3)               |
| ≥24 Months                                  | 16 (64.0)              |

WBI: Whole-brain irradiation.

**Table II. Survival rates at 3 and 6 months following WBI (univariate analyses).**

| Factor                                      | At 3 months (%) | At 6 months (%) | p-Value |
|---------------------------------------------|-----------------|-----------------|---------|
| Radiation regimen                           |                 |                 |         |
| 5×4 Gy                                      | 75              | 50              | 0.226   |
| 10×3 Gy                                     | 42              | 17              |         |
| >30 Gy (2-3 Gy per fraction)                | 25              | 13              |         |
| Age                                         |                 |                 |         |
| ≤75 Years                                   | 44              | 22              | 0.831   |
| ≥76 Years                                   | 40              | 20              |         |
| Gender                                      |                 |                 |         |
| Female                                      | 33              | 22              | 0.829   |
| Male                                        | 47              | 20              |         |
| Karnofsky performance score                 |                 |                 |         |
| <60                                         | 45              | 9               | 0.521   |
| ≥70                                         | 38              | 31              |         |
| Number of cerebral metastases               |                 |                 |         |
| Limited (1-3)                               | 57              | 43              | 0.194   |
| Multiple (>3)                               | 35              | 12              |         |
| Extra-cranial metastases at the start of WBI|                 |                 |         |
| No                                          | 33              | 22              | 0.902   |
| Yes                                         | 47              | 20              |         |
| Time from kidney cancer diagnosis to WBI    |                 |                 |         |
| <24 Months                                  | 38              | 0               | 0.107   |
| ≥24 Months                                  | 44              | 31              |         |

WBI: Whole-brain irradiation.

The median survival time following WBI in all 24 patients was 3 months, and the post-WBI 3-month and 6-month survival rates were 42% and 21%, respectively.

Two of the factors, namely number of cerebral metastases (p=0.194) and the time from kidney cancer diagnosis to WBI (p=0.107), showed a trend for an association with survival and were, therefore, included in the scoring instrument (Table II). The following factor points were assigned: 1-3 cerebral metastases=1 point, >3 cerebral metastases=0 points, time from kidney cancer diagnosis to WBI ≥24 months=1 point, and time from kidney cancer diagnosis to WBI <24 months=0 points. Thus, patient scores of 0, 1 and 2 points were produced. The corresponding 3-month survival rates were 33%, 38% and 60%, respectively, and the corresponding 6-month survival rates were 0%, 15% and 60%, respectively (p=0.131). Based on these survival rates, two prognostic groups were designed, namely 0-1 points (n=19) and 2 points (n=5). The survival rates of these two groups were 37% and 60%, respectively, at 3 months, and 11% and 60%, respectively, at 6 months (p=0.108, Figure 1).

**Discussion**

The prognoses of many patients with metastatic kidney cancer are poor. However, due to the recent introduction of novel systemic agents such as checkpoint inhibitors, patients with extracranial metastatic disease live longer (13-15). This likely has an impact on the risk of developing cerebral metastases, which increases with lifetime. Of the entire group of patients with cerebral metastases from kidney cancer, a considerable proportion was elderly. These patients should be analyzed separately due to significant comorbidities and reduced reserve. Many of these patients may be unable to withstand aggressive treatment regimens. Therefore, they likely will benefit from personalized treatment approaches that consider among other aspects a patient's survival prognosis. In general, patients with poor prognoses assigned to WBI should receive a WBI-regimen with a short overall treatment time, e.g. 5×4 Gy given in 1 week. In a previous retrospective study including patients...
with poor prognoses and cerebral metastases of any age and with different primary tumor types, 5×4 Gy (n=232) was not associated with worse outcomes than 10×3 Gy in 2 weeks (n=210) in terms of local control (p=0.07) and survival (p=0.29) (11). Moreover, the rates of grade 3 acute toxicities were also not significantly different. On the contrary, patients with favorable survival prognoses may benefit from WBI with higher total doses and lower dose per fraction (16, 17). In longer-term survivors receiving WBI for cerebral metastases, total doses >30 Gy resulted in better local control and survival. One-year local control rates were 28% after 10×3 Gy and 44% after 20×2 Gy (p=0.047 on multivariate analysis), and 1-year survival rates were 50% and 61%, respectively (p=0.008 on multivariate analysis) (16). Moreover, WBI with doses per fraction of <3.0 Gy were reported to result in less prominent neuro-cognitive dysfunction when compared to ≥3.0 Gy (17). Thus, when aiming to assign the optimal WBI-regimen to a patient, it is important to estimate a patient’s remaining lifespan. To achieve this goal, physicians can use scoring instruments (survival scores) that are available for several primary tumor types (18-20). In this study, a specific instrument for elderly kidney cancer patients has been created. This new instrument includes two prognostic groups, 0-1 and 2 points. The 6-month survival probability after radiation therapy for brain metastases from renal cell carcinoma. Anticancer Res 35: 3571-3574, 2015. PMID: 26026128.

**Conflicts of Interest**

On behalf of all Authors, the corresponding Author states that there are no conflicts of interest related to this study.

**Authors’ Contributions**

D.R., T.N. and S.E.S participated in the design of the study. T.N. and D.R. provided the data. Analyses of the data were performed by S.E.S. and D.R. The article was drafted by D.R. and S.E.S., and reviewed and approved by all Authors.

**References**

1. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA and Chang EL: Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2: 210-225, 2012. PMID: 25925626. DOI: 10.1016/j.prro.2011.12.004
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019. PMID: 30620402. DOI: 10.3322/caac.21551
3. Rades D, Huttenlocher S, Gebauer N, Hornung D, Trang NT, Khoa MT and Schild SE: Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Res 35: 3571-3574, 2015. PMID: 26026128.
4. Janssen S, Dahlke M, Trang NT, Khoa MT and Rades D: Estimation of the six-month survival probability after radiosurgery for brain metastases from kidney cancer. Anticancer Res 35: 4215-4217, 2015. PMID: 26124381.
5. Rades D, Dziggel L, Blanck O, Gebauer N, Bartscht T and Schil SE: Predicting the risk of developing new cerebral lesions after stereotactic radiosurgery or fractionated stereotactic radiotherapy for brain metastases from renal cell carcinoma. Anticancer Res 38: 2973-2976, 2018. PMID: 29715126. DOI: 10.21873/anticancer.12548
6. Rades D, Pluemer A, Veninga T and Schild SE: Comparison of different treatment approaches for one to two brain metastases in elderly patients. Strahlenther Onkol 184: 565-571, 2008. PMID: 19016014. DOI: 10.1007/s00066-008-1908-1
7. Hansen HC, Janssen S, Schild SE and Rades D: Estimating survival of patients with metastatic renal cell carcinoma receiving whole-brain radiotherapy with a new tool. Anticancer Res 39: 2091-2095, 2019. PMID: 30952754. DOI: 10.21873/anticancer.13321
8 Dziggel L, Segedin B, Podvršnik NH, Oblak I, Schild SE and Rades D: A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone. Strahlenther Onkol 190: 54-58, 2014. PMID: 23861153. DOI: 10.1007/s00066-013-0394-2

9 Meyners T, Heisterkamp C, Kueter JD, Veninga T, Stalpers LJ, Schild SE and Rades D: Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer 10: 582, 2010. PMID: 20977700. DOI: 10.1186/1471-2407-10-582

10 Rades D, Heisterkamp C and Schild SE: Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys 78: 398-403, 2010. PMID: 20488627. DOI: 10.1016/j.ijrobp.2009.08.022

11 Rades D, Kieckebusch S, Lohynska R, Veninga T, Stalpers LJ, Dunst J and Schild SE: Reduction of overall treatment time in patients irradiated for more than three brain metastases. Int J Radiat Oncol Biol Phys 69: 1509-1513, 2007. PMID: 17689033. DOI: 10.1016/j.ijrobp.2007.05.014

12 Evers JN, Schild SE, Segedin B, Nagy V, Khoa MT, Trang NT and Rades D: A new score predicting survival prognosis after whole-brain radiotherapy alone for brain metastases in elderly patients. Anticancer Res 34: 2455-2458, 2014. PMID: 24778060.

13 Vuorinen RL, Paunu N, Turpeenniemi-Hujanen T, Reunamo T, Jekunen A, Kataja V, Sintonen H, Purmonen T and Kellokumpu-Lehtinen PL: Sunitinib First-line treatment in metastatic renal cell carcinoma: costs and effects. Anticancer Res 39: 5559-5564, 2019. PMID: 31570450. DOI: 10.21873/anticancer.13749

14 Ueda K, Yonekura S, Ogasawara N, Matsunaga Y, Hoshino R, Kurose H, Chikui K, Uemura K, Nakiri M, Nishihara K, Matsuo M, Suekane S and Igawa T: The impact of antibiotics on prognosis of metastatic renal cell carcinoma in Japanese patients treated with immune checkpoint inhibitors. Anticancer Res 39: 6265-6271, 2019. PMID: 31704856. DOI: 10.21873/anticancer.13836

15 Hillebrand RM, Vogt A, Strassburg CP, Gonzalez-Carmona MA and Schmidt-Wolf IGH: Immune check point CD40-CD40L activates dendritic and effector cells against human renal carcinoma cells. Anticancer Res 39: 4643-4652, 2019. PMID: 31519562. DOI: 10.21873/anticancer.13645

16 Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R and Schild SE: Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118: 3852-3859, 2012. PMID: 22170514. DOI: 10.1002/cncr.26680

17 DeAngelis LM, Delattre JY and Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789-796, 1989. PMID: 2725874. DOI: 10.1212/wnl.39.6.789

18 Rades D, Dziggel L, Bartsch T and Gliemroth J: Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Res 34: 6763-6765, 2014. PMID: 25368288.

19 Rades D, Dziggel L, Manig L, Janssen S, Khoa MT, Duong VN, Khiem VH and Schild SE: Predicting survival after whole-brain irradiation for cerebral metastases in patients with cancer of the bladder. In Vivo 32: 633-636, 2018. PMID: 29695570. DOI: 10.21873/inivo.11285

20 Janssen S, Hansen HC, Schild SE and Rades D: An instrument for estimating the 6-month survival probability after whole-brain irradiation alone for cerebral metastases from gynecological cancer. Anticancer Res 38: 3753-3756, 2018. PMID: 29848738. DOI: 10.21873/anticancer.12656

Received February 1, 2020

Revised February 11, 2020

Accepted February 12, 2020